About UCSF Search UCSF UCSF Medical Center

Christopher C. Benz, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
benz_christopher

Adjunct Professor, Department of Medicine, UCSF

cbenz@buckinstitute.org

Phone: (415) 209-2092 (voice)
Box 1270, UCSF


Education

University of California, Los Angeles, B.S., 1968, Biochemistry
University of Michigan, Ann Arbor, M.D., 1972, Medicine
VGH/CCABC & UBC, Vancouver, B.C., Canada, 1972-1978, Int Med/Hem-Onc
Yale Univ. School of Med, New Haven, CT, 1978-79, Oncology

Professional Experience

  • 1979-1982
    Postdoctoral Associate, Oncology-Pharmacology, Yale University School of Medicine
  • 1981-1982
    Instructor, Department of Medicine, Yale University School of Medicine
  • 1982-1982
    Assistant Professor of Medicine, Yale University School of Medicine
  • 1983-1982
    Assistant Professor of Medicine, University of California, San Francisco
  • 1984-1982
    Director, UCSF Hormone Receptor Laboratory
  • 1988-1992
    Associate Professor of Medicine, UCSF
  • 1991-present
    Faculty of Molecular Medicine, UCSF
  • 1994-present
    Professor of Medicine in Residence, UCSF (converted to Adjunct Professor, 9/2000)
  • 1994-1992
    Acting Director, UCSF Cancer Research Institute
  • 1995-present
    Member, Joint UCSF-UCB Graduate Group in Bioengineering
  • 1997-1992
    Visiting Scientist/Professor of Mol. Medicine, Univ. Basel & Friedrich Miescher Inst., Basel
  • 2000-present
    Director, Cancer and Developmental Therapeutics Program, Buck Institute for Age Research

Selected Publications

  • 105. Scott GK, MattieMD, Berger C, Benz SC, and Benz CC. Rapid alteration of microRNA levels byhistone deacetylase inhibition. Cancer Res. 66: 1277-1281, 2006.
  • 106. Kumar AS,Campbell M, Benz CC, and Esserman LJ. A call for clinical trials:lipophilicstatins may prove effective in treatment and prevention of particularbreastcancer subtypes. J. Clin. Oncol. 24: 2127, 2006.
  • 107. Kumar AS, BenzCC, and Esserman LJ. Clinical trials are required to prove thechemopreventiveworth of statins. Arch. Intern. Med. 166: 1143, 2006.
  • 108. Marx C, BergerC, Xu F, Amend C, Scott GK, Hann B, Park JW, and Benz CC. Validatedhigh-throughput screening of drug-like small molecules for inhibitors ofErbB2transcription. ASSAY and Drug Development Technologies 4: 273-284, 2006.
  • 109. Urban P,Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E, Senn H-J, BenzC,Eppenberger U, and Eppenberger-Castori S. Increased expression ofurokinase-type plasminogen activator mRNA determines adverse prognosis inErbB2-positive primary breast cancer. J. Clin. Oncol. 24: 4245-4253, 2006.
  • 110. Campbell MJ,Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner R, Kumar AS,AdduciK, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, and Benz CC. Breastcancer growth prevention by statins. Cancer Res. 66: 8707-8714, 2006.
  • 111. Hayes ME, Drummond DC, KirpotinDB, Zheng WW, Noble CO IV, Park JW, Marks JD, Benz CC, and Hong K.Genospheres:self-assembling nucleic acid-lipid nanoparticles suitable for targetedgenedelivery. Gene Therapy, 13: 646-651, 2006.
  • 112. Kirpotin DB,Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB, Marks JD, Benz CC,andPark JW. Antibody targeting of long-circulating lipidic nanoparticles doesnotincrease tumor localization but does increase internalization in animalmodels.Cancer Res. 66: 6732-6740, 2006
  • 113. Mattie MD, BenzCC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, GettsR,and Haqq C. Optimized high-throughput microRNA expression profilingprovidesnovel biomarker assessment of clinical prostate and breast cancerbiopsies.Molecular Cancer 5:24, 2006.
  • 114. Kumar AS,Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, and Hwang ES.Typeand duration of exogenous hormone use impacts breast cancer histology.Ann.Surg. Oncol. 14: 695-703, 2007.
  • 115. Benz CC, FedeleV, Xu F, Ylstra B, Ginzinger D, Yu M, Moore D, Hall RK, Wolf D, Disis ML,Eppenberger-Castori S, Eppenberger U, Schittulli F, Tommasi S, Paradiso A,ScottGK, and Albertson DG. Altered promoter usage characterizes monoallelictranscription arising with ERBB2amplification in human breast cancers. Genes, Chromosomes & Cancer 45:983-994, 2006.
  • 116. Hayes ME, Drummond DC, Hong K.Zheng WW, Khorosheva VA, Cohen JA, Noble CO IV, Park JW, Marks JD, BenzCC, andKirpotin DB. Increased target specificity of anti-HER2 genospheres bymodification of surface charge and degree of PEGylation. MolecularPharmaceutics 3: 726-736, 2006.
  • 117. Tommasi S,Fedele V, Lacalamita R, Bruno M, Schittulli F, Ginzinger D, Scott G,Eppenberger-Castori S, Calistri D, Casadei S, Seymour I, Longo S,Giannelli G,Pilato B, Simone G, Benz CC, and Paradiso A. 655Val and 1170Pro ERBB2 SNPsinfamilial breast cancer risk and BRCA1 alterations. Cell Oncol. 29:241-248,2007.
  • 118. Scott GK, GogaA, Bhaumik D, Berger CE, Sullivan CS, and Benz CC. Coordinate suppressionof ERBB2 and ERBB3 by enforced expression of microRNA miR-125a ormiR-125b. J.Biol. Chem. 282: 1479-1486, 2007.
  • 119. Benz CC, AtsrikuC, Yau C, Britton D, Schilling B, Gibson BW, Baldwin MA, and Scott GK.Novelpathways associated with quinone induced stress in breast cancer cells.DrugMetabolism Reviews 38: 601-613, 2006.
  • 120. Vuaroqueaux V,Urban P, Labuhn M, Delorenzi M, Wirapati P, Benz CC, Flury R, Dieterich H,Spyratos F, Eppenberger U, Eppenberger-Castori S. Low E2F1 transcriptlevelsare a strong determinant of favorable breast cancer outcome. Breast CancerResearch 9: R33, 2007.
  • 121. Roth A, DrummondDC, Conrad F, Hayes M, Kirpotin DB, Benz CC, Marks JD, and Liu B.Anti-CD166single chain antibody-mediated intracellular delivery of liposomal drugstoprostate cancer cells. Mol. Cancer Therapeutics 6: 2737-2746, 2007.
  • 122. Zhou Y, Yau C,Gray JW, Chew K, Dairkee SH, Moore DH, Eppenberger U, Eppenberger-CastoriS,and Benz CC. Enhanced NFkB and AP-1 transcriptional activity associatedwithantiestrogen resistant breast cancer. BMC Cancer 7: 59, 2007.
  • 123. Park JW, NeveRM, Szollosi J, and Benz CC. Unraveling the biologic and clinicalcomplexitiesof HER2. Clinical Breast Cancer 8: 392-401, 2008.
  • 124. Atsriku C, BenzCC, Scott GK, Gibson BW, and Baldwin MA. Quantification of cysteineoxidationin human estrogen receptor by mass spectrometry. Anal. Chem. 79:3083-3090,2007.
  • 125. Marx, C, Yau C,Banwait S, Zhou Y, Scott GK, Hann B, Park JW, and Benz CC. ProteasomeregulatedERBB2 and estrogen receptor pathways in breast cancer. MolecularPharmacology71: 1525-1534, 2007.
  • 126. Benz CC, CampisiJ, Cohen HJ, Ershler WB, Haubein L, Irminger-Finger I. Meeting Report:Translational research at the aging and cancer interface. Cancer Res. 67:4560-4563, 2007.
  • 127. Kumar AS, BenzCC, Shim V, Minami CA, Moore DH, and Esserman LJ. Estrogenreceptor-negativebreast cancer is less likely to arise among lipophilic statin users.CancerEpidemiology, Biomarkers and Prevention 17: 1028-1033, 2008. (Editorialcomment: Byers T. Statins, breast cancer, and an invisible switch. CancerEpidemiology, Biomarkers and Prevention 17: 1026-1027, 2008.
  • 128. Yau C, Fedele V,Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, MooreDH,Schittulli F, Tommasi S, Paradiso A, Albertson DG, and Benz CC. Agingimpactstranscriptome but not genome of hormone-dependent breast cancers. BreastCancerResearch 9: R59, 2007.
  • 129. Goga A and BenzCC. Anti-oncomir suppression of tumor phenotypes. Mol. Interventions. 7:199-202, 2007.
  • 130. Benz CC. Impactof aging on the biology of breast cancer. Critical Reviews inOncology/Hematology. 66: 65-74, 2008.
  • 131. Britton DJ,Scott GK, Schilling B, Atsriku C, Held J, Gibson BW, Benz CC., and BaldwinMA.A novel serine phosphorylation site detected in the N-terminal domain ofestrogen receptor isolated from human breast cancer cells. J. Am. Soc.Mass.Spectrom. 19: 729-740, 2008. (+ Journal cover image from article)
  • 132. Scott GK, MarxC, Berger CE, Saunders LR, Verdin E, Schäfer S, Jung M, and Benz CC.Destabilization of ERBB2 transcripts by targeting 3¹UTR mRNA associatedHuR andhistone deacetylase-6 (HDAC6). Mol Cancer Res. 6: 1250-1258, 2008. (+Journalcover image from article)
  • 133. Bhaumik D, ScottGK, Schokrpur S, Patil CK, Campisi J, and Benz CC. Expression of microRNA146suppresses NF-kB activity with reduction of metastatic potential inbreast cancer cells. Oncogene 27: 5643-5647, 2008.
  • 134. Yau C, and BenzCC. Genes responsive to both oxidant stress and loss of estrogen receptor(ER)function identify a poor prognosis group of ER-positive primary breastcancers.Breast Cancer Res. 10: R61, 2008. (editorial;Neven P, Van Gorp T, and Deraedt K, BCR 10:109, 2008) (responding comment;Benz CC and Yau C, Relationship of Ox-E/ERsignature expression with clinical parameters and outcome inage-stratifiedcohorts, BCR, http://breast-cancer-research.com/content/10/5/109/comments#310608
  • 135. Benz CC and YauC. Aging, oxidative stress, and cancer: paradigms in parallax. NatureReviewsCancer 8: 875-879, 2008.
  • 136. Atsriku C,Britton DJ, Held JM, Schilling B, Scott GK, Gibson BW, Benz CC, andBaldwin MA.Systematic mapping of posttranslational modifications in human estrogenreceptor alpha, with emphasis on novel phosphorylation sites. MolecularCellular Proteomics 8: 467-480, 2009.
  • 137. Noble CO, Guo Z,Hayes ME, Marks JD, Park JW, Benz CC, Kirpotin DB, and Drummond DC.Characterization of highly stable liposomal and immunoliposomalformulations ofvincristine and vinblastine. Cancer Chemotherapy and Pharmacology 64:741-751,2009.
  • 138. Drummond DR,Noble CO, Guo Z, Hayes ME, Connoly-Ingrim C, Gabriele B, Hann B, Liu B,ParkJW, Hong K, Benz CC, Marks JD, and Kirpotin DB. Development of highlystableand targetable nanoliposomal formulation of topotecan. J. ControlledRelease141: 13-21, 2010.
  • 139. Suzuki J, ChenY-Y, Scott GK, DeVries S, Chin K, Benz CC, Waldman FM, Hwang ES. Proteinacetylation and histone deacetylase expression associated with malignantbreastcancer progression. Clin. Cancer Res. 15: 3163-3171, 2009.
  • 140. Hurst DR,Edmonds MD, Scott GK, Benz CC, and Welch DR. Breast cancer metastasissuppressor 1 BRMS1 up-regulates miR-146 that suppresses breast cancermetastasis. Cancer Res. 69: 1279-1283, 2009. (+ image on journal cover)
  • 141. Coppe J-P, AmendC, Semeiks J, Baehner FL, Bayani N, Campisi J, Benz CC., Gray JW, and NeveRM.ERBB receptor regulation of ESX/ELF3 promotes invasion in breastepithelialcells. The Open Cancer Journal 3: 89-100, 2010.
  • 142. Ereman RR,Prebil LA, Mockus M, Koblick K, Orenstein F, Benz CC, and Clarke CA.Recenttrends in hormone therapy utilization and breast cancer incidence rates inthehigh incidence population of Marin County, California. BMC Public Health10:228, 2010.
  • 143. Held JM, BrittonDJ, Scott GK, Schilling B, Puckett RL, Baldwin MA, Gibson BW, and Benz CC.Ligand restricted phosphorylation of estrogen receptor-a atserine-294. (submitted, 2009).
  • 144. Held JM,Danielson SR, Behring JB, Atsriku C, Britton DJ, Puckett RL, Schilling B,Campisi J, Benz CC, and Gibson BW. Targeted quantitation of site-specificcysteine oxidation in endogenous proteins using a differential alkylationandmultiple reaction monitoring mass spectrometry approach. MolecularCellularProteomics 9: 1400-1410, 2010.
  • 145. Marx C, Held JM,Gibson BW, and Benz CC. ErbB2 trafficking and degradation associated withK48and K63 polyubiquitination. Cancer Research 70: 3709-3717, 2010.
  • 146. Yau C, EssermanL, Moore DH, Waldman F, Sninsky J, and Benz CC. A multigene predictor ofmetastatic outcome in early stage receptor-negative and triple-negativebreastcancer. Breast Cancer Research 12:R85, 2010.
  • 147. Pettersson F,Yau C, Dobocan MC, Culjkovic-Kralijacic B, Retrouvay H, Puckett R,Cocolakis E,Borden KLB, Benz CC, and Miller, WH. Ribavirin treatment effects on breastcancers overexpressing eIF4E, a biomaker with prognostic specificity forluminal B-type breast cancer. Clin. Cancer Res. 17: 2874-2884, 2011.
  • 148. Yau C, Wang Y,Zhang Y, Foekens JA, and Benz CC. Young age, increased tumor proliferationandFOXM1 expression predict early metastatic relapse only forendocrine-dependentbreast cancers. Breast Cancer Res. Treat. 126: 803-810, 2011.
  • 149. The CancerGenome Atlas Research Network (including CC Benz). Integrated genomicanalysesof ovarian carcinoma. Nature 474: 609-615, 2011.
  • 150. Esserman LJ,Moore DH, Tsing P, Chu P, Yau C, Ozanne E, Chung RE, Tandon MJ, Park J,BaehnerFL, Kreps S, Tutt ANJ, Gillett CE, and Benz CC. Biologic markers determineboththe risk and the timing of recurrence in breast cancer. Breast Cancer Res.Treat.129: 607-616, 2011.